In the US state of Florida, the Senate Appropriations Committee hasvoted 14-7 to approve legislation which would allow generic substitution for some brand-name medicines, including DuPont's Coumadin (warfarin sodium), which are currently exempted from state legislation which requires pharmacists to offer generics unless a doctor specifically orders against it (Marketletters passim).
Committee chairman Senator Jim Home attempted to amend the bill to require doctors to specify whether they want the patient to receive a generic or the brand-name drug, but the vote was tied and the amendment was not approved.
The battle in Florida's state legislature over lifting the exemption has been going on for the last three years, and the Senate Health, Aging and Long-Term Care Committee approved the legislation, SB 342, earlier this year (Marketletter March 5).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze